-
Dizziness and vertigo are among the most common complaints seen by neurologists, and benign paroxysmal positional vertigo is one of their most frequent causes.
-
Azithromycin is an effective, single-drug therapy for mild-to-moderate community-acquired pneumonia.
-
Eighty-seven percent or more of patients with fatal or nonfatal myocardial infarction have major risk factors prior to the event.
-
Patients with unexplained chronic fatigue and bodily pain are more likely to have rhinosinusitis symptoms than are people in the general population.
-
Insulin 70/30 Mix Plus Metformin vs Triple Oral Therapy in Type 2 Diabetes; ARB and ACE-I in Diabetic Nephropathy; Low-Glycemic Index Diets and Diabetes
-
Vardenafil has been approved for the treatment of erectile dysfunction in men. The drug is the second oral type 5 phosphodiestase (PDE5) inhibitor approved for this indication along with sildenafil (Viagra).
-
There are arguments about the optimal treatment for ulcers with nonbleeding visible vessels and adherent clots. This study showed that the combination of endoscopic hemostasis with IV proton pump inhibitor therapy is superior to PPI alone in management of such patients.
-
In this sophisticated analysis of ECG-LVH regression, more than 9000 hypertensive patients were randomized to losartan or atenolol therapy, treated to target blood pressure levels, and followed for up to 5 years.
-
Schoffs and colleagues looked at the occurrence of hip fracture (excluding pathologic fractures and fractures in prosthetic hips) from 1991 to 1999 and their relationship to thiazide diuretics and chlorthalidone, which is not strictly a thiazide, but behaves like one.
-
The FDA has approved vardenafil (LevitraBayer and GlaxoSmithKline) for
the treatment of erectile dysfunction in men. Vardenafil joins
sildenafil (Viagra) as the only 2 drugs approved for this indication in
this country.